The Application of PET/CT in Predicting and Evaluating the Therapeutic Response in Chemotherapy of Solid Tumor

doi:10.7538/tws.2016.youxian.045

Abstract

Abstract:

Three aspects of the application of PET/CT in solid tumor chemotherapy were summarized, including the selection of evaluation criteria, the proper time of using PET/CT in the evaluation and the parameters of PET/CT in evaluating the response of chemotherapy. It showed that when using PET/CT in the evaluation of chemotherapy efficacy, suitable evaluation method according to the different characteristics of tumor and chemotherapy should be chosen, and perfect designed researches needed to confirm the conclusions.

Key words:

positron emission tomography, solid tumor, chemotherapy, predicton of therapeutic response

摘要：

本文从评价标准、评价时间和评价参数三方面对PET/CT用于实体肿瘤化疗疗效评价进行总结，结果表明，使用PET/CT进行化疗疗效评价时，应根据不同肿瘤和化疗的特点选择适合的评价手段，对评价手段的确定性需设计完善的研究进一步验证。

关键词:

正电子发射计算机断层显像（PET/CT）, 实体肿瘤, 化疗, 预测及疗效评价

CHEN Mei-jie;CHEN Song;YIN Ya-fu;LI Ya-ming. The Application of PET/CT in Predicting and Evaluating the Therapeutic Response in Chemotherapy of Solid Tumor[J]. Journal of Isotopes, 2017, 30(2): 148-152.

陈美洁;陈松;尹雅芙;李亚明. PET/CT在预测及评价实体肿瘤化疗疗效中的应用[J]. 同位素, 2017, 30(2): 148-152.

References

［1］Wahl R L, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors［J］. Journal of Nuclear Medicine, 2009, 50 Suppl 1(2): 122S-150S.
［2］Huang W, Zhou T, Ma L, et al. Standard uptake value and metabolic tumor volume of ¹⁸F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced nonsmall cell lung cancer［J］. European Journal of Nuclear Medicine and Molecular Imaging,2011, 38(9): 1628-1635.
［3］Novello S, Vavalà T, Levra M G, et al. Early response to chemotherapy in patients with non-small-cell lung cancer assessed by ［¹⁸F］-Fluoro-Deoxy-D-Glucose positron emission tomography and computed tomography［J］. Clinical Lung Cancer,2013, 14(3): 230-237.
［4］Roedl J B, Colen R R, Holalkere N S, et al. Adenocarcinomas of the esophagus: Response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT comparison to histopathologic and clinical response evaluation［J］. Radiotherapy and Oncology, 2008, 89(3): 278-286.
［5］Kidd E A, Thomas M, Siegel B A, et al. Changes in cervical cancer FDG uptake during chemoradiation and association with response［J］. International Journal of Radiation Oncology Biology Physics,2013, 85(1): 116-122.
［6］Yanagawa M, Tatsumi M, Miyata H, et al. Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors［J］. Journal of Nuclear Medicine, 2012, 53(6): 872-880.
［7］Swisher S G, Maish M, Erasmus J J. Utility of PET/ CT and EUS to jdentify pathologic responders in esophageal cancer［J］. Annals Thoracic Surgery,2004, 78(78): 1152-1160.
［8］Ott K, Weber W A, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction［J］. Journal of Clinical Oncology, 2006, 24(29): 4692-4698.
［9］de Geus-Oei L F, van H F, Visser E P, et al. Chemotherapy response evaluation with ¹⁸F-FDG PET in patients with non-small cell lung cancer［J］. Journal of Nuclear Medicine,2007, 48(10): 1592-1598.
［10］Nahmias C, Hanna W T, Wahl L M, et al. Time course of early response to chemotherapy in non-small cell lung cancer patients with ¹⁸F-FDG -PET/CT［J］. Journal of Nuclear Medicine, 2007, 48(5): 744-751.
［11］Weber W A, Petersen V, Schmidt B, et al. Positron emission tomography in nonsmall cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use［J］. Journal of Clinical Oncology,2003, 21(14): 2651-2657.
［12］Francis R J, Byrne M J, van A A, et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial ¹⁸F-FDG PET scans［J］. Journal of Nuclear Medicine,2007, 48(9): 1449-1458.
［13］Janssen M H M, llers M C, Riedl R G, et al. Accurate prediction of pathological rectal tumor response after two weeks of preoperative radiochemotherapy using (18)F-fluorodeoxyglucose-positron emission Tomography-computed Tomography Imaging［J］. International Journal of Radiation Oncology Biology Physics,2010, 77(2): 392-399.
［14］Dutour A, Decouvelaere A V, Monteil J, et al. ¹⁸F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model［J］. Journal of Nuclear Medicine, 2009, 50(9): 1533-1540.
［15］Dose S J, Bader M, Jenicke L, et al. Early prediction of response to chemotherapy in metastatic breast cancer using sequential ¹⁸F-FDG PET［J］. Journal of Nuclear Medicine,2005, 46(7): 1144-1150.
［16］Zhu W, Xing L, Yue J, et al. Prognostic significance of SUV on PET/CT in patients with localized oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation: a systematic review and meta analysis［J］. The British Journal of Radiology, 2012, 85(1017): e694-e701.
［17］Kaira K, Endo M, Asakura K, et al. Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer［J］. Annal of Nuclear Medicine,2010, 24(10): 697-705.
［18］Na I I, Byun B H, Kang H J, et al.18F-fluoro-2-deoxy-glucose uptake predicts clinical outcome in patients with gefitinib treated non-small cell lung cancer［J］. linical Cancer Research, 2008, 14(7): 2036-2041.
［19］Yamamoto M, Tsujikawa T, Fujita Y, et al. Metabolic tumor burden predicts prognosis of ovarian cancer patients who receive platinum-based adjuvant chemotherapy［J］. Cancer Science, 2016: 107(4): 478-485.
［20］Heijmen L, ter Voert E E, Oyen W J, et al. Multimodality imaging to predict response to systemic treatment in patients with advanced colorectal cancer［J］. PLoS One, 2015: 10(4): e0120823.
［21］Kiyohara S, Nagamachi S, Wakamatsu H, et al. Usefulness of metabolic volume and total lesion glycolysis for predicting therapeutic response in cancer therapy by 18F-FDG PET/CT［J］. The Japanese Journal of Nulear Medicine,2010, 47(4): 453-461.
［22］Cook G J R, Yip C, Siddique M, et al. Are pretreatment ¹⁸F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?［J］. Journal of Nuclear Medicine,2013, 54(1): 19-26.
［23］Guillem J G, Ruby J A, Leibold T, et al. Neither FDG-PET nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective study［J］. Annals of Surgery, 2013, 258(2): 289-295.
［24］Lee P, Bazan J G, Lavori P W, et al. Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer［J］. Clinical Lung Cancer, 2011, 13(1): 52-58.
［25］Fonti R, Larobina M, Del Vecchio S,et al. Metabolic tumor volume assessed by ¹⁸F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma［J］. Journal of Nuclear Medicine,2012, 53(12): 1829-1835.
［26］Zhang H, Wroblewski K, Liao S, et al. Prognostic value of metabolic tumor burden from ¹⁸F-FDG PET in surgical patients with nonesmall-cell lung cancer［J］. Academic Radiology,2013, 20: 32-40.
［27］Manohar K, Mittal B R, Bhattacharya A, et al. Prognostic value of quantitative parameters derived on initial staging ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with high-grade non-hodgkin’s lymphoma［J］. Nuclear Medicine Communications, 2012, 33(9): 974-981.
［28］Liu J, Dong M, Sun X, et al.Prognostic value of ¹⁸F-FDG PET/CT in surgical non-small cell lung cancer: a meta-analysis［J］. PLoS One,2016,11(1): e0146195.
［29］Bazan J G, Koong A C, Kapp D S, et al. Metabolic tumor volume predicts disease progression and survival in patients with squamous cell carcinoma of the anal canal［J］. Journal of Nuclear Medicne,2013, 54(1): 27-32.